Albert Bourla, CEO of Pfizer, Charlie Scharf, Wells Fargo & Firm CEO and Kathy Warden, Northrop Grumman Chair & CEO converse in the course of the Put money into America Discussion board on Oct. 15, 2025.
Aaron Clamage | CNBC
Wells Fargo CEO Charlie Scharf and Pfizer CEO Albert Bourla sounded the alarm Wednesday over the potential for the the U.S. to lose its aggressive edge to China, however stated synthetic intelligence may assist America keep its lead.
Talking at CNBC’s inaugural Put money into America Discussion board in Washington, D.C., the 2 executives stated that whereas the U.S. nonetheless leads in lots of sectors, inconsistent coverage and underinvestment is ceding floor to China. AI, they stated, poses each dangers and advantages for the U.S. economic system.
Scharf stated AI will possible scale back the dimensions of workforces — however will increase productiveness.
“We are going to possible have much less individuals, completely,” Scharf stated. “After we take a look at the instruments that we have carried out simply for those that are coding, you see 20%, 30%, 40% enchancment in coders. We’ve not lowered our head depend by 20%, 30% or 40%. We’re truly doing greater than we in any other case would have been in a position to do.”
Wells Fargo large financial institution friends like JPMorgan and Goldman Sachs are already hiring fewer individuals due to AI developments.
Scharf additionally stated the monetary sector is poised for main regulatory modifications regardless of an ongoing political stalemate in Washington.
“We finally do count on vital modifications in capital necessities, liquidity necessities,” he stated. “We do count on to see modifications which is able to permit individuals within the trade, not simply large banks and medium-sized banks, however smaller banks as properly, to do extra in these [local] communities.”
Bourla, in the meantime, expressed concern about China’s rising energy in biotechnology and prescription drugs, pointing to a surge in analysis and improvement spending, regulatory reforms and a nationwide technique targeted on life sciences.
“They [China] filed extra patents this 12 months than the U.S.,” Bourla stated. “That is by no means occurred in historical past. 5 years in the past, the cut up was 90%-10%. … The hole is closing, however they in all probability will turn into [better than us] until we get our act collectively.”
Bourla urged the U.S. to shift focus from attempting to gradual China’s progress towards bettering its personal productiveness and innovation.
“We spend extra time attempting to consider learn how to decelerate China reasonably than assume how we are able to turn into higher than them,” Bourla stated. “We have to have regulatory modifications right here. We have to have stability. Tariffs and pricing was not serving to.”
Pfizer not too long ago agreed to a drug pricing cope with the Trump administration as a part of a broader effort to take away long-standing uncertainties round pricing, Medicaid reimbursements and distribution. As a part of the settlement, Pfizer secured a three-year exemption from pharmaceutical-specific tariffs, contingent on extra investments in U.S. manufacturing.
“Tariffs and the uncertainty of drastic correction of U.S. pricing — with this deal, we’re eradicating each uncertainties,” Bourla stated Wednesday.
He additionally known as synthetic intelligence the following frontier for medication, predicting that AI will revolutionize drug discovery by dramatically accelerating timelines for locating therapies for illnesses like Alzheimer’s and most cancers.
“We tried for years to seek out cures … AI will make it occur,” Bourla stated.